EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    6.1.1.15 | Idiopathic Pulmonary Fibrosis |
30524284 |
Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix Proteins: Implications for Idiopathic Pulmonary Fibrosis. |
causal interaction
ongoing research
unassigned |
3
2
0 |
| 6.1.1.15 | Intestinal Volvulus |
31046663 |
Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths. |
therapeutic application
unassigned |
4
0 |
| 6.1.1.15 | Leishmaniasis |
28867614 |
Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. |
therapeutic application
unassigned |
4
0 |
| 6.1.1.15 | Malaria |
25047712 |
Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase. |
therapeutic application
unassigned |
1
0 |
| 6.1.1.15 | Malaria |
25569515 |
Halofuginone - the multifaceted molecule. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 6.1.1.15 | Malaria |
25995223 |
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. |
causal interaction
therapeutic application
unassigned |
1
2
0 |
| 6.1.1.15 | Malaria |
27798837 |
Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. |
therapeutic application
unassigned |
4
0 |
| 6.1.1.15 | Malaria |
28867614 |
Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. |
therapeutic application
unassigned |
4
0 |
| 6.1.1.15 | Neoplasms |
17018635 |
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. |
diagnostic usage
therapeutic application
unassigned |
1
1
0 |
| 6.1.1.15 | Neoplasms |
27612429 |
EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer. |
causal interaction
unassigned |
3
0 |
